Porous bidirectional bellowed tracheal reconstruction device

• US 9,180,029 B2
• Filed: 12/14/2012
• Issued: 11/10/2015
• Est. Priority Date: 12/14/2011
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Hollister, Scott J., Green, Glenn E.
• Primary Examiner(s): Prone, Christopher D.
• Assistant Examiner(s): Diop, Rokhaya
• Application Number:
  US13/715,715
• Publication Number:
  US 20130158651A1
• Time in Patent Office: 1,061 Days
• Field of Search: 623/1.14, 623/1.15, 623/1.38, 623/1.39, 623/23.64, 623/23.7, 623/23.75, 623/23.76, 623/1.1, 623/1.11, 623/1.12, 623/1.2, 623/9, 623/23.65, 128/207.14
• US Class Current: 1/1
• CPC Class Codes: A61F 2/848 having means for fixation to the vessel wall, e.g. barbs
• CPC Class Codes: A61F 2/94 Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
• CPC Class Codes: A61F 2002/043 Bronchi
• CPC Class Codes: A61F 2002/044 Oesophagi or esophagi or gullets
• CPC Class Codes: A61F 2002/046 Tracheae
• CPC Class Codes: A61F 2220/0008 Fixation appliances for connecting prostheses to the body
• CPC Class Codes: A61F 2220/0075 sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
• CPC Class Codes: A61F 2220/0091 connected by a hinged linkage mechanism, e.g. of the single-bar or multi-bar linkage type
• CPC Class Codes: A61L 31/005 Ingredients of undetermined constitution or reaction products thereof
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: B29C 64/153 using layers of powder being selectively joined, e.g. by selective laser sintering or melting
• CPC Class Codes: B29K 2067/00 Use of polyesters or derivatives thereof, as moulding material
• CPC Class Codes: B29K 2105/251 Particles, powder or granules expandable particles B29K2105/046
• CPC Class Codes: B29K 2995/0056 Biocompatible, e.g. biopolymers or bioelastomers
• CPC Class Codes: B29L 2031/7534 Cardiovascular protheses
• CPC Class Codes: B33Y 10/00 Processes of additive manufacturing
• CPC Class Codes: B33Y 80/00 Products made by additive manufacturing
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

Implantable splinting devices for supporting a passageway defect in a patient that is formed from one or more support structures including a polymer or a polymer and acellularized tissue matrix that define a structural component that substantially conforms to a defective passageway of the patient. The structural component also has a plurality of pores. The implantable splinting device is capable of being placed around a trachea, a bronchi, an esophagus and a blood vessel of a patient. The implantable splinting device may also be configured for placement between the trachea, and the esophagus of a patient.

Claims

1. An implantable splinting device for supporting a defect in a passageway of a human or other animal subject comprising:

one or more bellow support structures together defining a structural component that substantially conforms to at least a portion of the passageway and a plurality of apertures defined in at least a portion of the one or more bellow support structures, wherein the one or more bellow support structures comprise a biocompatible polymeric material, so that the structural component is capable of restricting displacement to less than 10% under a direct compression load of about 50 Newtons (N), while permitting outward radial displacement of at least 100% of an initial diameter of the structural component under non-stress conditions under a radial pressure of about 50 Newtons (N).

2. The implantable splinting device of claim 1, wherein the biomedically polymeric material is polycaprolactone and has a degradation time of from about 10 months to about 24 months.

3. The implantable splinting device of claim 1, wherein the implantable splinting device is designed from a set of medical image data specific to the human or other animal subject.

4. The implantable splinting device of claim 1, wherein the implantable splinting device is designed for placement around and substantially conforms to at least a portion of the passageway selected from the group consisting of:

a trachea, a bronchi, an esophagus, and a blood vessel.

5. The implantable splinting device of claim 1, wherein the passageway defect is selected from the group consisting of:

tracheomalacia, tracheoesophageal fistula, tracheoinnominate fistula, congenital stenosis, acquired stricture, cancer (obstruction from tumors), idiopathic tracheomalacia, tracheal/airway reconstruction surgery, bronchomalacia, weakened veins and a coronary bypass.

6. The implantable splinting device of claim 1, wherein the structural component has an inner diameter and an outer diameter, wherein the inner diameter ranges from greater than or equal to about 4 mm to less than or equal to about 30 mm and the outer diameter ranges from greater than or equal to about 5 mm to less than or equal to about 34 mm, and wherein the implantable splinting device has a length ranging from greater than or equal to about 10 mm to less than or equal to about 60 mm.

7. The implantable splinting device of claim 1, wherein the biomedically polymeric material comprises a biodegradable polymer.

8. The implantable splinting device of claim 7, wherein the biodegradable polymer is polycaprolactone.

9. The implantable splinting device of claim 1, wherein the implantable splinting device further comprises a bioactive agent, wherein the bioactive agent is selected from the group consisting of:

a cell adhesion factor, an isolated tissue material, a growth factor, a peptide, a cytokine, a hormone, a pharmaceutically active combinations, and combinations thereof.

10. The implantable splinting device of claim 9, wherein the implantable splinting device comprises acellularized dermis, an acellularized tissue matrix, a composite of acellularized dermis matrix and polymer, or a composite of acellularized tissue matrix and polymer.

11. The implantable splinting device of claim 1, wherein a wave period of the one or more bellow support structures is greater than or equal to about 1.5 mm to less than or equal to about 6 mm.

12. The implantable splinting device of claim 11, wherein each of the one or more bellow support structures comprises a protruding region and a recessed region.

13. The implantable splinting device of claim 12, wherein a first length of the protruding region is greater than or equal to about 1 mm to less than or equal to about 4 mm and a second length of the recessed region is greater than or equal to about 0.5 mm to less than or equal to about 2 mm.

14. The implantable splinting device of claim 1, wherein the structural component further comprises a longitudinal opening formed within the one or more bellow support structures to facilitate placement of the implantable splinting device over the portion of the passageway and a width of the longitudinal opening ranges from greater than or equal to about 4 mm to less than or equal to about 15 mm.

15. The implantable splinting device of claim 1, wherein the plurality of apertures respectively has a diameter ranging from about 0.5 mm to about 3 mm.

16. A method of making an implantable splinting device for application to a passageway defect in a human or other animal subject comprising:

designing a structural component for the implantable splinting device from a set of medical image data of the passageway defect specific to the subject;

laser sintering or three-dimensional (3D) printing a biocompatible polymeric material to form the structural component comprising one or more bellow support structures that substantially conform to at least a portion of the passageway; and

integrating a plurality of pores within the structural component capable of receiving a suture for attaching the implantable splinting device to at least a portion of the passageway, wherein the structural component is capable of restricting displacement to less than 10% under a direct compression load of about 50 Newtons (N), while permitting outward radial displacement of at least 100% of an initial diameter of the structural component under non-stress conditions under a radial pressure of about 50 Newtons (N).

17. The method of claim 16, wherein the implantable splinting device is configured for placement around at least a portion of the passageway of the subject selected from the group consisting of:

a trachea, a bronchi, an esophagus and a blood vessel.

18. Previously Presented) The method of claim 16, wherein the biocompatible polymeric material is polycaprolactone and has a degradation time from about 10 months to about 24 months.